These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28468948)

  • 41. Immune checkpoint blockade: a common denominator approach to cancer therapy.
    Topalian SL; Drake CG; Pardoll DM
    Cancer Cell; 2015 Apr; 27(4):450-61. PubMed ID: 25858804
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
    Hirai M; Kitahara H; Kobayashi Y; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
    Int J Oncol; 2017 Jan; 50(1):41-48. PubMed ID: 27922697
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy.
    Liu K; Huang J; Liu J; Li C; Kroemer G; Tang D; Kang R
    Cancer Res; 2022 May; 82(10):2003-2018. PubMed ID: 35247909
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
    Furness AJ; Quezada SA; Peggs KS
    Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
    [No Abstract]   [Full Text] [Related]  

  • 46. New immunotherapies targeting the PD-1 pathway.
    Chinai JM; Janakiram M; Chen F; Chen W; Kaplan M; Zang X
    Trends Pharmacol Sci; 2015 Sep; 36(9):587-95. PubMed ID: 26162965
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer.
    Henick BS; Herbst RS; Goldberg SB
    Expert Opin Ther Targets; 2014 Dec; 18(12):1407-20. PubMed ID: 25331677
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Not Available].
    Senant M; Giusti D; Weiss L; Dragon-Durey MA
    Bull Cancer; 2016 Nov; 103 Suppl 1():S175-S185. PubMed ID: 28057182
    [TBL] [Abstract][Full Text] [Related]  

  • 49. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
    Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
    Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overcoming T cell exhaustion in infection and cancer.
    Pauken KE; Wherry EJ
    Trends Immunol; 2015 Apr; 36(4):265-76. PubMed ID: 25797516
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.
    Lee V; Murphy A; Le DT; Diaz LA
    Oncologist; 2016 Oct; 21(10):1200-1211. PubMed ID: 27412392
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients.
    Sui X; Ma J; Han W; Wang X; Fang Y; Li D; Pan H; Zhang L
    Oncotarget; 2015 Aug; 6(23):19393-404. PubMed ID: 26305724
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune checkpoints and their inhibition in cancer and infectious diseases.
    Dyck L; Mills KHG
    Eur J Immunol; 2017 May; 47(5):765-779. PubMed ID: 28393361
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gut microbes shape response to cancer immunotherapy.
    Kaiser J
    Science; 2017 Nov; 358(6363):573. PubMed ID: 29097525
    [No Abstract]   [Full Text] [Related]  

  • 57. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Qian JM; Yu JB; Kluger HM; Chiang VL
    Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.
    Chen L; Han X
    J Clin Invest; 2015 Sep; 125(9):3384-91. PubMed ID: 26325035
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protocol to prepare functional cellular nanovesicles with PD1 and TRAIL to boost antitumor response.
    Yu P; Zheng D; Zhang C; Wu M; Liu X
    STAR Protoc; 2021 Mar; 2(1):100324. PubMed ID: 33604583
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IFN Signaling and ICB Resistance: Time is on Tumor's Side.
    López-Soto A; Gonzalez S; Folgueras AR
    Trends Cancer; 2017 Mar; 3(3):161-163. PubMed ID: 28718428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.